UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results on Wednesday, July 30th. The company reported earnings of $6.41 per share, missing estimates of $7.08 by $0.67. The company also reported revenue of $798,600,000, missing estimates of $820,369,312 by $-21,769,312.
You can see Quiver Quantitative's $UTHR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UNITED THERAPEUTICS Insider Trading Activity
UNITED THERAPEUTICS insiders have traded $UTHR stock on the open market 144 times in the past 6 months. Of those trades, 0 have been purchases and 144 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:
- PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 53 sales selling 99,000 shares for an estimated $29,393,494.
- MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 62 sales selling 41,679 shares for an estimated $14,284,513.
- RAY KURZWEIL has made 0 purchases and 9 sales selling 15,000 shares for an estimated $4,755,151.
- JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 5 sales selling 12,000 shares for an estimated $3,904,496.
- RAYMOND DWEK has made 0 purchases and 3 sales selling 10,000 shares for an estimated $2,850,390.
- TOMMY G THOMPSON has made 0 purchases and 3 sales selling 7,500 shares for an estimated $2,355,693.
- CHRISTOPHER PATUSKY has made 0 purchases and 7 sales selling 5,000 shares for an estimated $1,553,584.
- RICHARD GILTNER sold 3,036 shares for an estimated $879,214
- NILDA MESA sold 645 shares for an estimated $187,045
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
UNITED THERAPEUTICS Hedge Fund Activity
We have seen 335 institutional investors add shares of UNITED THERAPEUTICS stock to their portfolio, and 309 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WEALTHFRONT ADVISERS LLC removed 18,313,441 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $5,645,484,457
- WELLINGTON MANAGEMENT GROUP LLP removed 437,475 shares (-17.8%) from their portfolio in Q1 2025, for an estimated $134,860,418
- VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. removed 328,783 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $94,475,795
- FMR LLC removed 326,802 shares (-22.2%) from their portfolio in Q1 2025, for an estimated $100,743,252
- JANUS HENDERSON GROUP PLC removed 277,607 shares (-59.2%) from their portfolio in Q1 2025, for an estimated $85,577,909
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 275,226 shares (+inf%) to their portfolio in Q1 2025, for an estimated $84,843,919
- ALLIANCEBERNSTEIN L.P. removed 254,060 shares (-35.8%) from their portfolio in Q1 2025, for an estimated $78,319,076
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
UNITED THERAPEUTICS Government Contracts
We have seen $961,494 of award payments to $UTHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BULK ORDER TYVASO: $89,934
- BULK PHARMACY TYVASO: $88,161
- TYVASO: $48,094
- OPSUMIT 10MG-QTY 2 @ 6,270.03 ADEMPAS 1MG, QTY 1 @ 12,153.05 JULY 2025: $37,233
- TYVASO 48 AND 64 MCG KITS NDCS: 66302-0648-03, 66302-0664-03: $31,959
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
UNITED THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $UTHR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 06/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/05/2025
- JP Morgan issued a "Overweight" rating on 05/01/2025
To track analyst ratings and price targets for UNITED THERAPEUTICS, check out Quiver Quantitative's $UTHR forecast page.
UNITED THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $UTHR recently. We have seen 7 analysts offer price targets for $UTHR in the last 6 months, with a median target of $330.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $328.0 on 07/10/2025
- Jessica Fye from JP Morgan set a target price of $330.0 on 07/08/2025
- Ashwani Verma from UBS set a target price of $385.0 on 06/30/2025
- Greg Harrison from B of A Securities set a target price of $315.0 on 06/11/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $405.0 on 06/02/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $425.0 on 05/05/2025
- Tiago Fauth from Wells Fargo set a target price of $314.0 on 04/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
